8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Jul 26, 2013)

Filed July 26, 2013For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed a Form 8-K on July 26, 2013, primarily to report its financial results for the second quarter of 2013. This filing includes a press release detailing the company's operational performance and financial condition for the period. Investors should review the furnished press release for specific details on revenue, earnings, and any significant operational developments during the quarter. The key takeaway for investors is the direct disclosure of AbbVie's Q2 2013 financial performance. While the 8-K itself is a procedural document, the attached press release is the substantive information investors will be analyzing to assess the company's trajectory and compare its performance against expectations and prior periods.

Key Highlights

  • 1AbbVie Inc. reported its second quarter 2013 financial results.
  • 2The 8-K filing was made on July 26, 2013, with an event date of July 25, 2013.
  • 3The primary purpose of the filing is to disclose financial results and operational performance.
  • 4The detailed Q2 2013 results are provided in an accompanying press release (Exhibit 99.1).
  • 5William J. Chase, Executive Vice President and Chief Financial Officer, signed the report, indicating executive oversight of the financial disclosures.
  • 6The filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  • 7This report serves as a key regulatory update on AbbVie's financial standing at the time.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report AbbVie Inc.'s financial results for the second quarter of 2013. It includes a press release that contains the detailed operational and financial performance for the period.

The specific financial details are provided in the press release dated July 26, 2013, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.

The report is signed by William J. Chase, who is the Executive Vice President and Chief Financial Officer of AbbVie Inc., indicating his authorization and responsibility for the financial disclosures.

The event date typically signifies when the material event (in this case, the earnings announcement) occurred or was determined, while the filing date is when the company officially submitted the report to the SEC. This timing suggests AbbVie announced its Q2 2013 results on July 25th and filed the necessary 8-K report the following day.